Related Experiment Videos
[Benefits and risks of antiplatelet therapy. A retrospective study]
1Department of Internal Medicine, School of Medicine, Fukuoka University.
Insights
Antiplatelet agents significantly reduce the risk of recurrent cerebral infarction. These medications do not increase the incidence of cerebral hemorrhage, offering a safe option for stroke prevention.
Area of Science:
- Neurology
- Pharmacology
Context:
- Cerebral infarction is a leading cause of long-term disability.
- Preventing recurrent strokes is a critical clinical challenge.
- Antiplatelet agents are commonly used, but their safety profile regarding hemorrhagic complications requires ongoing evaluation.
Purpose:
- To evaluate the efficacy of antiplatelet agents in preventing recurrent cerebral infarction.
- To assess the risk of cerebral hemorrhage as an adverse effect of antiplatelet therapy.
Summary:
- A retrospective study of 746 patients with cerebral infarction (excluding cardiogenic embolism) investigated the impact of antiplatelet agents.
- Recurrence rates were lower in patients receiving antiplatelet agents (3.1%/year) compared to untreated patients (5.4%/year), with statistical significance (p < 0.01).
- The incidence of cerebral hemorrhage was similar in both groups (0.5%/year on antiplatelets vs. 0.6%/year off antiplatelets), indicating no increased risk associated with these drugs.
Impact:
- Antiplatelet therapy demonstrates significant effectiveness in reducing the risk of recurrent cerebral infarction.
- The findings suggest that antiplatelet agents can be safely administered for secondary stroke prevention without a notable increase in cerebral hemorrhage risk.
Abstract:
Seven hundred and forty-six patients with cerebral infarction (except those with cardiogenic embolism) were retrospectively studied to determine the effect of antiplatelet agents on the prevention of recurrence and the incidence of cerebral hemorrhage, as an adverse effect of the drugs. The average follow-up period was 26.5 months for the fatal cases and 41.3 months for the survivors. Cerebral infarction recurred in 41 patients (3.1%/year) during the period of administration of antiplatelet agents, while it occurred in 66 (5.4%/year) untreated patients (p less than 0.01). Cerebral hemorrhage occurred 14 times in 14 patients; 7 (0.5%/year) during the antiplatelet treatment and 7 (0.6%/year) during the period without antiplatelet agents. No evidence was found that cerebral hemorrhage was promoted by antiplatelet agents.